Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
New Phase II data show vast majority of patients experiencing no relapses or disability progression
The Unit has been issued GMP Certification from ANVISA-Brazil
Scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer and GSK will continue to vigorously defend itself against all claims
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Global Phase-3 study initiation expected in the second half of 2024
This facility manufactures APIs & formulations of oncology and non-oncology products.
A five-day inspection was concluded successfully with no critical and no major observations raised
ANVISA issues CGMP to Concord Biotech’s Unit I
Subscribe To Our Newsletter & Stay Updated